Skip to main content

The Model of a Medical Cannabis Clinic

  • Chapter
  • First Online:
Cannabinoids and Pain

Abstract

The development of medical cannabis clinics has emerged in recent years to meet needs from patients and healthcare practitioners amid changing medical cannabis regulations. As more countries are approving the use of cannabinoids for medical purposes, demand for access has increased but has not yet matched medical cannabis training. In countries where robust medical cannabis programs exist, patients are still utilizing illegal markets without adequate medical supervision, and physicians still report reluctance or barriers to prescription. The clinical use of cannabinoid-based treatments requires specific training, to support the careful assessment of patients; appropriate choice of product and chemovar; precise, personalized initiation and titration process; patient education; and continuous monitoring. Consequently, a well-trained multidisciplinary team is necessary to provide best clinical practice. A leading medical cannabis clinic in North America has created a unique model of care where clinical practice interacts with cannabinoid research development. At the clinic, coordinated patient education across physicians, nurses, pharmacists, and support staff plays a pivotal role to improve patient outcomes. Additionally, the unique, high-quality clinical experience has initiated the development of continuing medical education programs and partnership with recognized academic institutions. In a multidisciplinary environment, the creation of medical cannabis educational material and resources for healthcare practitioners and patients is supported by a peer review from the team of experts. Encouraging clinicians to be more engaged, or even to provide direct medical supervision, raises the awareness about cannabinoid potential risks and benefits and builds interest for further training. A focused medical cannabis practice or clinic allows for accelerated learning and experience, as diversity of patient cases is available at a high volume. Similarly, the unique setting allows for comprehensive data collection and the development of robust clinical research programs.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Azcarate PM, Zhang AJ, Keyhani S, Steigerwald S, Ishida JH, Cohen BE. Medical reasons for marijuana use, forms of use, and patient perception of physician attitudes among the US population. J Gen Intern Med. 2020;35:1979–86.

    Article  Google Scholar 

  2. Lintzeris N, Mills L, Suraev A, Bravo M, Arkell T, Arnold JC, et al. Medical cannabis use in the Australian community following introduction of legal access: the 2018-2019 Online Cross-Sectional Cannabis as Medicine Survey (CAMS-18). Harm Reduct J. 2020;17(1):37.

    Article  Google Scholar 

  3. Glickman A, Sisti D. Prescribing medical cannabis: ethical considerations for primary care providers. J Med Ethics. 2020;46(4):227–30.

    Article  Google Scholar 

  4. Arboleda MF, Prosk E, Cyr C, Gamaoun R, Vigano A. Medical cannabis in supportive cancer care: lessons from Canada. Support Care Cancer. 2020;28:2999–3001.

    Article  Google Scholar 

  5. Health Canada. Canadian cannabis survey 2019 – summary. 2019. Available from: https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/canadian-cannabis-survey-2019-summary.html.

  6. Wheeler M, Merten JW, Gordon BT, Hamadi H. CBD (cannabidiol) product attitudes, knowledge, and use among young adults. Subst Use Misuse. 2020;55(7):1138–45.

    Article  Google Scholar 

  7. Joypaul S, Kelly F, McMillan SS, King MA. Multi-disciplinary interventions for chronic pain involving education: a systematic review. PLoS One. 2019;14(10):e0223306.

    Article  CAS  Google Scholar 

  8. Davy C, Bleasel J, Liu H, Tchan M, Ponniah S, Brown A. Effectiveness of chronic care models: opportunities for improving healthcare practice and health outcomes: a systematic review. BMC Health Serv Res. 2015;15:194.

    Article  Google Scholar 

  9. Scholl I, Zill JM, Härter M, Dirmaier J. An integrative model of patient-centeredness - a systematic review and concept analysis. PLoS One. 2014;9(9):e107828.

    Article  Google Scholar 

  10. Abrams DI. The therapeutic effects of cannabis and cannabinoids: an update from the National Academies of Sciences, Engineering and Medicine report. Eur J Intern Med. 2018;49:7–11.

    Article  CAS  Google Scholar 

  11. Mahrer NE, Gold JI, Luu M, Herman PM. A cost-analysis of an interdisciplinary pediatric chronic pain clinic. J Pain. 2018;19(2):158–65.

    Article  Google Scholar 

  12. Joypaul S, Kelly FS, King MA. Turning pain into gain: evaluation of a multidisciplinary chronic pain management program in primary care. Pain Med Malden Mass. 2019;20(5):925–33.

    Article  Google Scholar 

  13. Reynolds HW, Sutherland EG. A systematic approach to the planning, implementation, monitoring, and evaluation of integrated health services. BMC Health Serv Res. 2013;13:168.

    Article  Google Scholar 

  14. Zylla D, Steele G, Eklund J, Mettner J, Arneson T. Oncology clinicians and the Minnesota Medical Cannabis Program: a survey on medical cannabis practice patterns, barriers to enrollment, and educational needs. Cannabis Cannabinoid Res. 2018;3(1):195–202.

    Article  Google Scholar 

  15. Atkinson TM, Rosenfeld BD, Sit L, Mendoza TR, Fruscione M, Lavene D, et al. Using confirmatory factor analysis to evaluate construct validity of the Brief Pain Inventory (BPI). J Pain Symptom Manag. 2011;41(3):558–65.

    Article  Google Scholar 

  16. Hui D, Bruera E. The Edmonton symptom assessment system 25 years later: past, present, and future developments. J Pain Symptom Manag. 2017;53(3):630–43.

    Article  Google Scholar 

  17. Matter-Walstra K, Klingbiel D, Szucs T, Pestalozzi BC, Schwenkglenks M. Using the EuroQol EQ-5D in Swiss cancer patients, which value set should be applied? PharmacoEconomics. 2014;32(6):591–9.

    Article  Google Scholar 

  18. Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344–64.

    Article  CAS  Google Scholar 

  19. Russo EB. Beyond cannabis: plants and the endocannabinoid system. Trends Pharmacol Sci. 2016;37(7):594–605.

    Article  CAS  Google Scholar 

  20. MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. Eur J Intern Med. 2018;49:12–9.

    Article  CAS  Google Scholar 

  21. Wilsey B, Atkinson JH, Marcotte TD, Grant I. The medicinal cannabis treatment agreement: providing information to chronic pain patients through a written document. Clin J Pain. 2015;31(12):1087–96.

    Article  Google Scholar 

  22. St Pierre M, Matthews L, Walsh Z. Cannabis education needs assessment among Canadian physicians-in-training. Complement Ther Med. 2020;49:102328.

    Article  Google Scholar 

  23. Ware MA, Ziemianski D. Medical education on cannabis and cannabinoids: perspectives, challenges, and opportunities. Clin Pharmacol Ther. 2015;97(6):548–50.

    Article  CAS  Google Scholar 

  24. Prescriber Training Program | Santé Cannabis. Available from: https://www.santecannabis.ca/en/physicians/to-prescribe-medical-cannabis/.

  25. Clark CS. Medical cannabis: the oncology nurse’s role in patient education about the effects of marijuana on cancer palliation. Clin J Oncol Nurs. 2018;22(1):E1–6.

    Article  Google Scholar 

  26. Graham M, Lucas CJ, Schneider J, Martin JH, Hall W. Translational hurdles with cannabis medicines. Pharmacoepidemiol Drug Saf. 2020;29:1325–30.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Maria Fernanda Arboleda .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Arboleda, M.F., Prosk, E. (2021). The Model of a Medical Cannabis Clinic. In: Narouze, S.N. (eds) Cannabinoids and Pain. Springer, Cham. https://doi.org/10.1007/978-3-030-69186-8_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-69186-8_19

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-69185-1

  • Online ISBN: 978-3-030-69186-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics